Therapeutic vaccine first stage one of hepatitis B publishes the result clinically

Therapeutic vaccine first stage one of hepatitis B publishes the result clinically
It is reported ' Reporter Sun GuoGen) Cooperate with institute of biological products of Beijing of our country first the intersection of hepatitis B and getting therapeutic vaccine that research and develop by the intersection of Fudan University and the intersection of Shanghai and the intersection of medical college and medical the intersection of molecule and the intersection of virus and laboratory ' Second gram) ,Finish the clinical test result analysis of the issue of the first stage recently. In the patient changing E antigenic serum after through one gram of treatments of second, 59.6% of the quantity in year of patient virus is dropped to clinically and negatively, 84.4% the intersection of patient and liver function return to normal, surface antigenic level drop, liver organize, examine while being alive and the intersection of cell and immunity appear inflammation relieve etc., indicate the second gram has better therapeutic effects to hepatitis B patient. This clinical trial adopts one pair of blind placeboes at random of many centres and contrasts the method according to the international standard strictly, regard institute of biological products of Fudan University and Beijing as and apply for the side, led by Beijing Temple of Earth hospital, Hangzhou Tigers medical Science Technologies Co., Ltd. supervises in the whole journey, the clinical research institution of 21 national medicines launches in the whole country. It is introduced, this test adopts internationally acknowledged most appropriate hepatitis B and virus E antigen (HBeAg) at present Serology is changed (E antigen that is duplicated and closely related with with hepatitis B and virus disappears, and E antibody appears) As the evaluation criterion of curative effect. Study the group according to the current antiviral treatment ' Use nucleoside medicine, interferon) Patient's therapeutic not less than one year experiences of chronic hepatitis B, have increased a course of treatment on the basis of �� stage B stage clinical trial, namely inject 12 pharmaceutical second grams to the chronic hepatitis B patient together, treat one to lengthen as one year for half a year, follow up a case by regular visits to 6 months. The first chronic hepatitis B patient enters the group from September of 2007, finish two courses of treatment to treat and follow up a case by regular visits to to all 518 patients, it lasts more than 3 years. The result shows, one gram of therapeutic groups and control group of patient E antigenic serum conversion ratio second does not have statistics difference. Though �� stage B stage and first stage and a clinical trial and E antigenic serum conversion ratio of the result two times are higher than not treating patient's natural conversion ratio of chronic hepatitis B, but take to expand sample quantity in order to further prove the curative effect of gram of second conclusively even.

|